ACBHealthcare · Drug Manufacturers - Specialty & GenericTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 59 of 100 as at 6 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Aurora Cannabis, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (80): Analysts have, on balance, been raising their forecasts.
Growth (18): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ACB, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 20 most recent actions, 0 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 27 June 2024 | Zuanic & Associates | Initiates | Neutral | — |
| 16 June 2023 | CIBC | Maintains | Neutral | $1.75 → $1.00 |
| 15 June 2023 | Canaccord Genuity | Maintains | Hold | $1.50 → $0.80 |
| 13 Feb 2023 | CIBC | Maintains | Neutral | $2.25 → $1.75 |
| 21 Sept 2022 | Piper Sandler | Maintains | Neutral | $4.00 → $3.00 |
| 28 Sept 2021 | MKM Partners | Upgrade | Neutral | — |
| 18 Dec 2020 | BMO Capital | Downgrade | Underperform | $9.00 |
| 25 Nov 2020 | B of A Securities | Downgrade | Neutral | — |
| 25 Nov 2020 | Bank of America | Downgrade | Neutral | — |
| 25 Nov 2020 | Cowen & Co. | Initiates | Outperform | — |
| 25 Nov 2020 | Desjardins | Initiates | Buy | — |
| 25 Nov 2020 | Jefferies | Initiates | Buy | — |
| 25 Nov 2020 | Ladenburg Thalmann | Downgrade | Neutral | — |
| 25 Nov 2020 | MKM Partners | Initiates | Sell | — |
| 25 Nov 2020 | Needham | Initiates | Hold | — |
| 25 Nov 2020 | Piper Jaffray | Maintains | Neutral | — |
| 25 Nov 2020 | Piper Sandler | Maintains | Neutral | — |
| 25 Nov 2020 | Seaport Global | Initiates | Neutral | — |
| 25 Nov 2020 | Stifel | Downgrade | Sell | — |
| 25 Nov 2020 | Stifel Nicolaus | Initiates | Hold | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ACB appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 7 Oct 2026, Aurora Cannabis, Inc. returned −27.7% against +17.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 36% of US stocks
Cheaper than 74% of US stocks
Cheaper than 81% of US stocks
Cheaper than 81% of US stocks
Higher than 17% of US stocks
Higher than 16% of US stocks
Higher than 65% of US stocks
Higher than 23% of US stocks
Higher than 12% of US stocks
Higher than 36% of US stocks
Higher than 34% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Aurora Cannabis, Inc. has a market value of $290.6M and an enterprise value of $155.1M.
Revenue in the twelve months to 30 June 2026: $290.1M. The latest quarter shrank 8.8% year on year.
Net income over the same four quarters: −$120.1M, a −41.4% net margin.
Free cash flow in the twelve months to 30 June 2026: −$51.2M.
Trailing P/E: 20.8×; forward P/E: −40.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Aurora Cannabis, Inc. employs 1,028 people — $282K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Aurora Cannabis, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Aurora’s Special Committee will conduct a thorough, independent review of Curaleaf’s revised hostile bid. The company advised shareholders to take no action until the Board issues a formal recommendation after the review is complete.
Why it matters — The review and pending Board recommendation are relevant to ACB shareholders assessing the revised bid.
MarketBeat reports that a multi-year cannabis bear market is giving way to industry consolidation, citing Curaleaf’s higher bid for Aurora and a shift in U.S. federal regulatory policy. Better-capitalized operators are seeking to secure global supply chains ahead of potential tax relief.
Why it matters — The higher bid and broader consolidation trend could affect Aurora’s position as cannabis operators pursue global supply chains.
Aurora Cannabis reiterated its recommendation that shareholders take no action at this time, as Curaleaf has not yet filed a Notice of Variation and Change to revise its hostile bid. Once the revised offer is filed, Aurora's Special Committee will perform a thorough review before issuing a formal recommendation; the company also noted that its application to the Alberta Securities Commission secured pro forma financials and a compliant bid timeline for shareholders.
Why it matters — ACB watchers would care because this update clarifies the ongoing hostile-bid process and the timeline and protections in place for shareholders as the company evaluates Curaleaf's revised offer.
Curaleaf has increased its offer for Aurora Cannabis by 25%, to a total implied value of $5 per Aurora share in cash and stock. The revised price is 86% above Aurora's 30-day volume-weighted average share price of $2.75 as of August 10.
Why it matters — ACB shareholders face a materially higher takeover valuation than the recent trading price, which could significantly affect the value of their holdings.
Curaleaf presented an unsolicited offer to acquire Aurora Cannabis for $4 per share, and Aurora rejected the bid, stating it did not fully value the company's business. The takeover attempt is reportedly encountering difficulties.
Why it matters — ACB watchers would care because the outcome of this hostile takeover attempt could significantly influence Aurora's valuation and strategic direction.
Of the 5 analysts covering Aurora Cannabis, Inc., 2 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Aurora Cannabis, Inc. 59 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 6 Oct 2026, Aurora Cannabis, Inc. ranks 59 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (80 of 100).
No analyst covering Aurora Cannabis, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ACB are extrapolating price history, which says nothing about the business.
Aurora Cannabis, Inc. returned -27.7% over the 12 months to 7 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Aurora Cannabis Inc. is a Canadian cannabis company focused on the production, distribution, and sale of cannabis and cannabis-derived products in Canada and international markets.
The most recent item we track (PRNewsWire, 6 Oct 2026): "Aurora Urges Shareholders to Take No Action to Revised Hostile Bid by Curaleaf as Formal Review Underway". Aurora’s Special Committee will conduct a thorough, independent review of Curaleaf’s revised hostile bid. The company advised shareholders to take no action until the Board issues a formal recommendation after the review is complete.
Aurora Cannabis Inc. is a Canadian cannabis company focused on the production, distribution, and sale of cannabis and cannabis-derived products in Canada and international markets. Aurora Cannabis Inc. serves both medical and consumer segments with offerings that include pharmaceutical-grade cannabis, dried flower, oils, capsules, concentrates, and other product formats designed for adult-use and therapeutic applications. The company operates through cannabis and plant propagation businesses, supporting a portfolio that spans branded consumer products, medical cannabis channels, and agricultural propagation activities. Headquartered in Edmonton, Alberta, Aurora Cannabis Inc. plays a notable role in the regulated cannabis industry by supplying patients, consumers, and wholesale partners across multiple regions.
CEO Mr. Miguel Martin · 1,028 employees · Canada · https://www.auroramj.com
